Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 9/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.35 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.35 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13985963 | 0.86 | CYP26A1 (0.30) | CYP26B1 | |
| SCHEMBL4512950 | 0.83 | FFAR1 (0.36) | RXRANR4A2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4512947 | 0.83 | FFAR1 (0.36) | RXRANR4A2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4506755 | 0.76 | CYP26A1 (0.43) | RXRAKDM4ECYP26B1ESR1 | |
| SCHEMBL4506757 | 0.76 | CYP26A1 (0.43) | RXRAKDM4ECYP26B1ESR1 | |
| SCHEMBL4507246 | 0.72 | BACE1 (0.38) | MEN1KMT2AESR1 | |
| SCHEMBL4507248 | 0.72 | BACE1 (0.38) | MEN1KMT2AESR1 | |
| SCHEMBL6821890 | 0.71 | RARA (0.60) | RXRAPIM2RARANPSR1CYP26B1 | |
| SCHEMBL6821889 | 0.71 | RARA (0.60) | RXRAPIM2RARANPSR1CYP26B1 | |
| SCHEMBL4526495 | 0.71 | CYP26A1 (0.42) | RXRARARACYP26B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638648-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7468391-B2 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | RXRA 351/4885NR4A2 959/4885PIM2 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.